Keyword Connections

pd-1

Journals

6

1 PloS one

2 International journal of biological macromolecules

3 Frontiers in immunology

4 European journal of cancer (Oxford, England : 1990)

5 Virology

6 journal of autoimmunity

Research Groups

0

No Research Group Connected

Bibliographies

45

1 Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp Risk Allele Drive the Expansion of FOXP3 Regulatory T Cells and PD-1 Expression.

2 Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.

3 Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.

4 Antimicrobial, anticancer and antioxidant activities of nano-heart of Phoenix dactylifera tree extract loaded chitosan nanoparticles: In vitro and in vivo study.

5 Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic.

6 the role of micrornas in aβ deposition and tau phosphorylation in alzheimer’s disease

7 pd-1/pd-l1 blockade: have we found the key to unleash the antitumor immune response?

8 cancer immunotherapies targeting the pd-1 signaling pathway

9 albumin/globulin ratio is negatively correlated with pd-1 and cd25 mrna levels in breast cancer patients

10 reversing egfr mediated immunoescape by targeted monoclonal antibody therapy

11 the efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials

12 prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma

13 advances of pd-1/pd-l1 inhibitors in tumor immunotherapy

14 Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

15 PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

16 Targeting Immune Cell Checkpoints during Sepsis

17 Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer

18 Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

19 Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy

20 Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.

21 First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

22 A tumor-targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma

23 Correlation of CpG methylation of Pdcd1 gene with PD-1 expression on CD8 T cells and medical laboratory indicators in chronic hepatitis B infection.

24 Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice

25 Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors.

26 Data analysis of PD-1 antibody in the treatment of melanoma patients.

27 [Preliminary study of PD-1 inhibitor in the treatment of drug-resistant recurrent gestational trophoblastic neoplasia]

28 checkpoint molecule pd-1-assisted cd8+ t lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

29 pd-1 regulates the growth of human mastocytosis cells

30 rescue therapy for patients with anti-pd-1-refractory merkel cell carcinoma: a multicenter, retrospective case series

31 opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-ctla-4 and anti-pd-1

32 anti-pd-1 and anti-ctla-4 therapies in cancer: mechanisms of action, efficacy, and limitations

33 enhancement of psma-directed car adoptive immunotherapy by pd-1/pd-l1 blockade

34 determination of dosimetric parameters of the second model of pd-103 seed manufactured at agricultural, medical and industrial research school

35 PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

36 EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes

37 Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.

38 The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report

39 The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report.

40 Galectin 7 leads to a relative reduction in CD4+ T cells, mediated by PD-1

41 Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination

42 Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination

43 Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response.

44 Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma.

45 Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study.